Articles published by BioInvent International
![](/users/newswire/images/678565/logo.jpg)
BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment
December 20, 2021
Via AccessWire
![](/users/newswire/images/678377/logo.jpg)
![](/users/newswire/images/677141/logo.jpg)
![](/users/newswire/images/676974/logo.jpg)
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
December 10, 2021
Via AccessWire
Tickers
CASI
![](/users/newswire/images/676499/logo.jpg)
![](/users/newswire/images/674695/logo.jpg)
![](/users/newswire/images/674388/logo.jpg)
BioInvent Hosting Key Opinion Leader Webinar on BI-1206
November 23, 2021
Via AccessWire
![](/users/newswire/images/671868/logo.jpg)
![](/users/newswire/images/671193/logo.jpg)
Via AccessWire
![](/users/newswire/images/670067/logo.jpg)
Via AccessWire
![](/users/newswire/images/670065/logo.jpg)
BioInvent International AB Interim Report January - September 2021
October 28, 2021
Via AccessWire
![](/users/newswire/images/669466/logo.jpg)
![](/users/newswire/images/666421/logo.jpg)
BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus at SITC 2021
October 01, 2021
Via AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.